Bander, Neil H.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics

Renal cell carcinoma treatmentEar and Head Tumors

Cited by 1,730

Tumor therapy with targeted atomic nanogenerators.

McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science

Radiopharmaceutical Chemistry and ApplicationsAdvanced Energy Technologies and Civil Engineering Innovations

Cited by 501

A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen

Rajasekaran, S. A., Anilkumar, G., Oshima, E., Bowie, J. U., Liu, H., Heston, W., Bander, N. H., & Rajasekaran, A. K. (2003) · Molecular Biology of the Cell

Cellular transport and secretionProstate Cancer Treatment and Research

Cited by 226

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591

Tagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Castellanos, S. H., Nauseef, J. T., Sternberg, C. N., et al. (2024) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 78

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

Milowsky, M. I., Galsky, M. D., Morris, M. J., Crona, D. J., George, D. J., Dreicer, R., Tse, K., Petruck, J., Webb, I. J., Bander, N. H., et al. (2016) · Urologic Oncology: Seminars and Original Investigations

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 78

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

Vlachostergios, P. J., Niaz, M. J., Sun, M., Mosallaie, S. A., Thomas, C., Christos, P. J., Osborne, J. R., Molina, A. M., Nanus, D. M., Bander, N. H., et al. (2021) · Frontiers in Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 43

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Tagawa, S. T., Sun, M. P., Nauseef, J. T., Thomas, C., Huicochea Castellanos, S., Thomas, J. E., Davidson, Z., Stangl-Kremser, J., Bissassar, M., Palmer, J., et al. (2023) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

Cited by 11

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Tagawa, S. T., Osborne, J., Fernandez, E., Thomas, C., Niaz, M. J., Ciriaco, A., Vallabhajosula, S., Vlachostergios, P. J., Molina, A. M., Sternberg, C. N., et al. (2020) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 10